March 1, 2018
Leggett Hails Opening of Viela Bio, MedImmune Spin-Out
Viela Bio will take its place alongside the many other successful biotech firms located in the County. Viela Bio’s work will focus on developing medicines for severe autoimmune diseases by targeting critical pathways at the root cause of disease. The company has announced a Series A financing with up to $250 million in investment capital.
Read more Here.
Press release from the Office of Governor Larry Hogan at New Biotech Company, Viela Bio, Launches in Maryland
More information from Viela Bio at Viela Bio Spins Out of MedImmune; Launches with Up to $250 Million Series A Financing from Investor Consortium Led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital